UY28080A1 - Isómeros posicionales del ifn peg alfa 2a - Google Patents

Isómeros posicionales del ifn peg alfa 2a

Info

Publication number
UY28080A1
UY28080A1 UY28080A UY28080A UY28080A1 UY 28080 A1 UY28080 A1 UY 28080A1 UY 28080 A UY28080 A UY 28080A UY 28080 A UY28080 A UY 28080A UY 28080 A1 UY28080 A1 UY 28080A1
Authority
UY
Uruguay
Prior art keywords
alfa
positional isomers
ifn
peg
ifn peg
Prior art date
Application number
UY28080A
Other languages
English (en)
Inventor
Alfred Schacher
Doris Brugger
Karl Weyer
Stefan Foser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY28080A1 publication Critical patent/UY28080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención concierne con isómeros posicionales del interferón alfa 2a monopegilado, con un método para su aislamiento y para su uso en la fabricación de medicacmentos para el tratamiento de enfermedades, especialmente para el tratamiento de enfermedades virales.
UY28080A 2002-11-15 2003-11-13 Isómeros posicionales del ifn peg alfa 2a UY28080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15

Publications (1)

Publication Number Publication Date
UY28080A1 true UY28080A1 (es) 2004-05-31

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28080A UY28080A1 (es) 2002-11-15 2003-11-13 Isómeros posicionales del ifn peg alfa 2a

Country Status (23)

Country Link
US (1) US20040223950A1 (es)
EP (1) EP1562634B1 (es)
JP (1) JP4279258B2 (es)
KR (1) KR20050065677A (es)
CN (1) CN1323722C (es)
AR (1) AR042039A1 (es)
AT (1) ATE337017T1 (es)
AU (1) AU2003293668A1 (es)
BR (1) BR0316227A (es)
CA (1) CA2503594C (es)
DE (1) DE60307881T2 (es)
ES (1) ES2270152T3 (es)
GT (1) GT200300244A (es)
MX (1) MXPA05005178A (es)
NO (1) NO20052310L (es)
PA (1) PA8587801A1 (es)
PE (1) PE20040834A1 (es)
PL (1) PL376883A1 (es)
RU (1) RU2005118752A (es)
TW (1) TW200413404A (es)
UY (1) UY28080A1 (es)
WO (1) WO2004045648A1 (es)
ZA (1) ZA200503756B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2004046365A2 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2553040A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
US7318918B2 (en) 2004-05-19 2008-01-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
KR20080037656A (ko) * 2005-06-20 2008-04-30 펩젠 코포레이션 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
EP2186830B1 (en) * 2007-09-04 2012-03-07 Biosteed Gene Expression Tech. CO., LTD. Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
DK2272875T3 (da) 2008-04-03 2014-03-31 Biosteed Gene Expression Tech Co Ltd Dobbeltstrenget polyethylenglycolmodificeret væksthormon, fremstillingsmetode samt anvendelse deraf
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
CN102014965B (zh) 2008-04-29 2015-11-25 阿森迪斯药物生长障碍股份有限公司 Peg化的重组人生长激素化合物
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
AU2003270341A1 (en) * 2002-09-05 2004-03-29 The General Hospital Corporation Modified asialo-interferons and uses thereof

Also Published As

Publication number Publication date
RU2005118752A (ru) 2006-02-10
DE60307881D1 (de) 2006-10-05
BR0316227A (pt) 2005-10-04
ZA200503756B (en) 2008-02-27
CN1711109A (zh) 2005-12-21
KR20050065677A (ko) 2005-06-29
CA2503594A1 (en) 2004-06-03
GT200300244A (es) 2004-06-03
AU2003293668A1 (en) 2004-06-15
WO2004045648A1 (en) 2004-06-03
JP2006515571A (ja) 2006-06-01
PA8587801A1 (es) 2004-09-16
CN1323722C (zh) 2007-07-04
TW200413404A (en) 2004-08-01
CA2503594C (en) 2011-05-10
ES2270152T3 (es) 2007-04-01
AR042039A1 (es) 2005-06-08
NO20052310D0 (no) 2005-05-11
PE20040834A1 (es) 2004-11-17
DE60307881T2 (de) 2007-03-08
PL376883A1 (pl) 2006-01-09
US20040223950A1 (en) 2004-11-11
ATE337017T1 (de) 2006-09-15
EP1562634A1 (en) 2005-08-17
NO20052310L (no) 2005-08-09
MXPA05005178A (es) 2005-07-22
JP4279258B2 (ja) 2009-06-17
EP1562634B1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
UY28080A1 (es) Isómeros posicionales del ifn peg alfa 2a
UY27720A1 (es) Aroilpiridinonas monocíclicas,
DOP2002000429A (es) Imidazotriazinas
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
AR037109A1 (es) Uso de flibanserina
BR0208636A (pt) Agente terapêutico para doenças de artrìtides crÈnicas de doenças relacionadas com inf‰ncia
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
BRPI0510654A (pt) formulações de interferon em hidrogel
AR052165A1 (es) Tratamiento de hepatitis c en la poblacion asiatica
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
UY28313A1 (es) Nonadepsipeptidos acilados
UY29189A1 (es) Nonadepsipeptidos acilados ii
UY28115A1 (es) Derivados del acido isoftalico
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
ECSP034872A (es) Nuevos heterociclos 3
UY27733A1 (es) Derivados de ciclopenteno.
GT199900167A (es) Nuevos bis-benzimidazoles.
AR049143A1 (es) Composiciones farmaceuticas de interferon beta (ifn beta) para tratamiento de la miocardiopatia y la disfuncion endotelial
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
EA200501625A1 (ru) Интерферон-бета при тяжелом остром респираторном синдроме (sars)
BRPI0406985A (pt) Terapia de combinação de hcv
DOP2002000404A (es) Nuevos heterocuclos 3.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150507